Skip to main content

Table 5 Multivariate stepwise regression analyses of data from 147 patients with axial spondyloarthritis followed over 2 years assessing the associations between treatment and development of erosion or fat metaplasia

From: Tumor necrosis factor inhibitor therapy but not standard therapy is associated with resolution of erosion in the sacroiliac joints of patients with axial spondyloarthritis

 

β coefficient

SE

t value

P value

2 year change in ASDAS

−0.43

0.15

−2.83

0.006

2 year change in SPARCC SIJ inflammation score

−0.077

0.032

−2.40

0.019

Baseline SSS score for fat metaplasia

0.085

0.039

2.16

0.034

  1. Dependent variable: 2-year change in SSS for fat metaplasia. Adjusted R2 = 0.18. Variables not included in the model: age, sex, symptom duration, treatment, baseline ASDAS, baseline and 2-year change in C-reactive protein, baseline SPARCC SIJ inflammation score, baseline SSS for backfill, and baseline SSS for erosion. ASDAS, Ankylosing Spondylitis Disease Activity Score; SE, standard error; SIJ, sacroiliac joint; SPARCC, Spondyloarthritis Research Consortium of Canada; SSS, sacroiliac joint structural score.